PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
38.05%
Revenue growth above 1.5x MRVL's 1.67%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
33.90%
Gross profit growth above 1.5x MRVL's 1.41%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-31.92%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-31.92%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
-36.35%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-34.78%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-36.76%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
0.87%
Share count expansion well above MRVL's 1.63%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
-0.28%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
No Data
No Data available this quarter, please select a different quarter.
816.19%
OCF growth above 1.5x MRVL's 32.42%. David Dodd would confirm a clear edge in underlying cash generation.
293.17%
FCF growth above 1.5x MRVL's 42.25%. David Dodd would verify if the firm’s strategic investments yield superior returns.
505.77%
10Y revenue/share CAGR 1.25-1.5x MRVL's 428.39%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
28.61%
5Y revenue/share CAGR under 50% of MRVL's 65.38%. Michael Burry would suspect a significant competitive gap or product weakness.
-6.24%
Both firms have negative 3Y CAGR. Martin Whitman would wonder if the entire market segment is in short-term retreat.
2606.74%
10Y OCF/share CAGR above 1.5x MRVL's 1154.54%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
111.21%
Below 50% of MRVL's 341.26%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
171.41%
3Y OCF/share CAGR at 75-90% of MRVL's 192.09%. Bill Ackman would press for improvements in margin or overhead to catch up.
-2169.33%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-961.70%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-313.69%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
1857.62%
Below 50% of MRVL's 8192.09%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
95.08%
5Y equity/share CAGR above 1.5x MRVL's 43.60%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
38.73%
3Y equity/share CAGR above 1.5x MRVL's 11.22%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.41%
Firm’s AR is declining while MRVL shows 28.49%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
-39.15%
Both reduce inventory yoy. Martin Whitman suspects a broader move to lean operations or industry slowdown in demand.
-5.13%
Negative asset growth while MRVL invests at 0.61%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-4.00%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-1.10%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
42.51%
We increase R&D while MRVL cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
37.51%
SG&A declining or stable vs. MRVL's 110.02%. David Dodd sees better overhead efficiency if it doesn't hamper revenue.